Charles Piller

But for people who are living on fixed incomes, they're still having out-of-pocket costs of thousands and thousands of dollars a year for this drug. To pay for it outright without insurance would cost in the many tens of thousands a year when you include the necessary brain scans to check for safety issues associated with this.

And of course, there's also the difficulty of taking the drugs, which is provided by infusions into your vein in a doctor's office. And this process has its own hazards. So I just want to say that This is a case where doctors are being asked by patients, should I take this drug? And I think many of them are saying, well, here are the costs and benefits of this. Here are the risks and benefits.

And of course, there's also the difficulty of taking the drugs, which is provided by infusions into your vein in a doctor's office. And this process has its own hazards. So I just want to say that This is a case where doctors are being asked by patients, should I take this drug? And I think many of them are saying, well, here are the costs and benefits of this. Here are the risks and benefits.

And of course, there's also the difficulty of taking the drugs, which is provided by infusions into your vein in a doctor's office. And this process has its own hazards. So I just want to say that This is a case where doctors are being asked by patients, should I take this drug? And I think many of them are saying, well, here are the costs and benefits of this. Here are the risks and benefits.

And for a person in your condition, here are the things you and your family need to consider. And I think what we've seen by the uptake being so slow, it suggests that a lot of people are just deciding not to do it. I think based on thoughtful comments and advice by doctors. Now, some doctors won't prescribe this drug because they're that concerned about it, but many will.

And for a person in your condition, here are the things you and your family need to consider. And I think what we've seen by the uptake being so slow, it suggests that a lot of people are just deciding not to do it. I think based on thoughtful comments and advice by doctors. Now, some doctors won't prescribe this drug because they're that concerned about it, but many will.

And for a person in your condition, here are the things you and your family need to consider. And I think what we've seen by the uptake being so slow, it suggests that a lot of people are just deciding not to do it. I think based on thoughtful comments and advice by doctors. Now, some doctors won't prescribe this drug because they're that concerned about it, but many will.

And I think even the ones that are prescribing it, many of them are saying, look, you have to weigh these for yourself. I can't tell you whether this is a good move for you or not. And really a lot of things in medicine, probably you can say much better than I can, really come down to that. They come down to a judgment call that the doctor and the patient have to collaborate on.

And I think even the ones that are prescribing it, many of them are saying, look, you have to weigh these for yourself. I can't tell you whether this is a good move for you or not. And really a lot of things in medicine, probably you can say much better than I can, really come down to that. They come down to a judgment call that the doctor and the patient have to collaborate on.

And I think even the ones that are prescribing it, many of them are saying, look, you have to weigh these for yourself. I can't tell you whether this is a good move for you or not. And really a lot of things in medicine, probably you can say much better than I can, really come down to that. They come down to a judgment call that the doctor and the patient have to collaborate on.

Yeah, that's a term we use in the field called shared decision-making. where a lot of times I think shared decision-making should be implemented throughout every decision that we do in healthcare, but especially in areas where the evidence isn't quite so clear one way or the other.

Yeah, that's a term we use in the field called shared decision-making. where a lot of times I think shared decision-making should be implemented throughout every decision that we do in healthcare, but especially in areas where the evidence isn't quite so clear one way or the other.

Yeah, that's a term we use in the field called shared decision-making. where a lot of times I think shared decision-making should be implemented throughout every decision that we do in healthcare, but especially in areas where the evidence isn't quite so clear one way or the other.

So a good example of this right now would probably be PSA testing or screening in otherwise healthy patients to potentially catch prostate cancer early. Before, in the past, we used to recommend it as a screening tool to catch prostate cancer early, and it was a higher-level recommendation.

So a good example of this right now would probably be PSA testing or screening in otherwise healthy patients to potentially catch prostate cancer early. Before, in the past, we used to recommend it as a screening tool to catch prostate cancer early, and it was a higher-level recommendation.

So a good example of this right now would probably be PSA testing or screening in otherwise healthy patients to potentially catch prostate cancer early. Before, in the past, we used to recommend it as a screening tool to catch prostate cancer early, and it was a higher-level recommendation.

Now it's moved back a bit to shared decision-making, where we talk about the risks you face, the potential downstream effects, the risk that you face based on your family history, et cetera, et cetera, and we come to the conclusion together whether or not to screen a healthy person, not when someone already has symptoms. That's a diagnostic test at that point.

Now it's moved back a bit to shared decision-making, where we talk about the risks you face, the potential downstream effects, the risk that you face based on your family history, et cetera, et cetera, and we come to the conclusion together whether or not to screen a healthy person, not when someone already has symptoms. That's a diagnostic test at that point.

Now it's moved back a bit to shared decision-making, where we talk about the risks you face, the potential downstream effects, the risk that you face based on your family history, et cetera, et cetera, and we come to the conclusion together whether or not to screen a healthy person, not when someone already has symptoms. That's a diagnostic test at that point.

So shared decision-making is really important. And I'm curious how the shared decision-making component was so poorly predicted by the pharma industry in this case, where they thought it was going to be a blockbuster drug.